





# The iTPA and Translation Manchester: Supporting Translational Research

UoM UK Biobank meeting 27<sup>th</sup> June 2019























## Wellcome Trust Institutional Translational Partnership Award (iTPA)

- £800k over 2 years to support Translational Research in Manchester
  - Translational Research Facilitators x2
  - Translational Funding Schemes x2

### Aim:





To facilitate a demonstrable shift in the translational research culture, engagement & productivity at the University of Manchester and associated NHS partners.


- Establish a Translational Research Office
- Increase engagement of researchers at UoM with translational research
- Advance researchers along the translational pipeline
- Reduce bottlenecks through increased support
- Increase collaborations between discovery scientists, clinicians and industry partners







## **Translational Research**









## **The Translational Pathway**

Discovery research to gain knowledge D1-D4

D2 No clinical,

Health, wellbeing or disease focus

**D3 Practical** outcome Proof of concept

**D4** optimisation Patient centred research T1-T3

T1 First evaluations in/ with people

T2 Statistical relevance reached

T2: when a

statistically relevant

number of events

demonstrate the

efficacy of the new

T3 **Evaluated** more widely

Translational research

Changes to healthcare, practise or treatment T4

> T4 Adopted by population health and policy

### Translatable research

D1: Pure basic research to gain knowledge

D1

practical or

commercial

application

D2: health or diseaseoriented/strategic research: To obtain new insight or a starting point for diagnosis, treatment or prevention.

### **Examples:**

**Establishing connections** between imaging data and disease.

Correlating genomics or proteomics and disease.

Health and wellbeing studies.

Epidemiological studies to identify links between environmental factors and disease.

D3: when the initial outcome of D2 research has been identified and its link to the disease has been confirmed

### **Examples:**

Target molecule or metabolic pathway identified and confirmed

D4: when the target from D3 is manipulated to confirm disease association.

### **Examples:**

Identifying a small molecule that alters target activity in a model system.

A diagnostic system based on a biomarker. Stimulation or blocking of an immune response.

### method or treatment is first validated in humans

T1: when a new

### **Examples:**

Phase 1 clinical trial First use of a device in a small target population First use of software in a clinical validation study Initial validation of a lifestyle intervention

### **Examples:**

approach

Phase 2 and 3 clinical trials Greater number of patients testing a device or lifestyle intervention Multiple clinical sites using newly developed software

### tested more generally

**Examples:** 

Phase 4 trials

routinely used

as superior to

existing tools

Use of device or

intervention being

Software identified

T3: when the new

approach is being

T4: translating findings to population health

### **Examples:**

Adoption into policy and/ or guidelines as a routine method or approach

http://documents.manchester.ac.uk/display.aspx?DocID=41767








## How we support Translational Researchers



Work with researchers to ensure translatability of projects



Form connections



Help identify, troubleshoot and overcome hurdles to translation



Develop pipelines



**Translation Manchester Network** 



Training







## How we support Translational Researchers: Funding

### Access to Expertise (A2E)

- Up to £25K per project for expert support to overcome a specific research hurdle within a translational project
- 15 projects supported to date

## Projects for Translation (P<sub>4</sub>T)

- Up to £55K per project to overcome a *translational hurdle* as part of an ongoing project
- 5 projects supported to date









## How we support Translational Researchers: Funding: A2E

#### 2018

- **1. Prof Kathryn Abel:** *mSootheBox:* Developing a Digital Health Intervention for Self Harm Management for Children and Young People
- 9 months access to <u>augmented reality expertise</u> and funds to establish an expert Research User Group
- **2. Dr Jordi Bella:** Cost of goods model for the manufacture of engineered recombinant collagens for tissue regeneration applications
- ➤ 6 months access to expertise to develop a cost of goods model
- **3. Dr Jeremy Derrick:** Stratification by Immuno-profiling of IgG in Rheumatoid Arthritis and Psoriasis Patients
- 3 months access to informatics expertise
- 4. Prof Tracy Hussell: Macrophage adaptation in the inflamed lung
- > 12 months access to clinician time for clinical sample collection
- **5. Dr Matthias Pierce:** 'CAPRI': Children and Adolescents with PaRental mental Illness: Understanding the 'who' and the 'how' of targeting interventions
- > 9 months access to an expert health economist
- **6. Dr Stephen Richardson:** *Development of an adipose stem cell-GDF6 regenerative therapy for intervertebral disc degeneration and back pain*
- > 9 months access to an expert health economist and expert Research User Group
- **7. Prof Mark Travis:** Determining a novel pathway that controls TGF-beta activation in the human immune system
- > 3 months access to research nurse and clinician time for clinical sample collection

#### 2019

- **1. Dr Silke Brix**: Risk stratification and modified immunotherapy to reduce mortality in elderly patients with ANCA-associated glomerulonephritis
- > 4 months access to statistical expertise
- 2. Dr Govind Oliver: Technology enhanced care in cardiac arrest
- 8 months access to software development expertise and clinician time
- **3. Prof Paul Bishop**: *In-silico prediction of potential for immunogenicity of AMD therapeutics*
- > 3 months access to in silico evaluation expertise
- **4. Dr Anna Woollams**: Using clinical imaging to optimise therapy for individuals with aphasia
- > 9 months access to app development and delivery expertise
- 5. Dr James Fildes: Developing an arterial leukocyte filter that mimics leukocyte adhesion
- ➤ 6 months access to <u>external peptide synthesis</u> expertise
- **6. Dr Jordi Bella**: Engineered recombinant collagens for tissue regeneration applications
- > 9 months access to expertise in <u>Target Product Profile development</u>
- **7. Prof Tony Day**: Development of Link-TSG6 as a protein biological with disease-modifying and anti-inflammatory properties
- > 5 months access to bioinformatics expertise
- **8. Dr Emma Gowen**: Developing a partnership between Autism@Manchester and GMMH NHS autism services
- 9 months access to clinician and research co-ordinator time







## How we support Translational Researchers: Funding: P4T

PI Name	Collaborators	Ongoing project
Brian Bigger	Sue Kimber (UoM) clean room facility, Rob Wynn & Simon Jones (MFT), iMATCH consortium (Manchester), (Indiana Vector core, Indiana USA)	Establish manufacturing scale-up of lentiviral transduction of peripheral blood derived CD34+ stem cells at GMP
Professor Tony Day (PI) & Dr Caroline Milner (CoI)		Development of Link_TSG6 as a protein biological with disease-modifying and anti-inflammatory properties
Mike Bromley	David Denning; Nick Read; Elaine Bignell, Jaya Chidambaram (Manchester Eye Hospital)	The Aspergillus fumigatus Gene and Non-Coding RNA Knockout Library.
Dr Ellen Poliakoff	Dr Jude Bek (UoM) Dr Emma Gowen (UoM)	Action Imagery and Observation in Neurorehabilitation for Parkinson's Disease (ACTION-PD)
Professor William Newman	Prof Craig Smith, Dr Dwaipayam Sen, John McDermott, SME Genedrive, Katherine Payne	Development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in neonates







### **Translatable/ Translational Areas**

Discovery/ fundamental science







Medical devices



Diagnostic imaging



Lifestyle interventions




Medical therapies



Software development



Treatment pathways



Medical procedures



Diagnostic tests



Education & training



Drug development



Technologies



Adoption to policy









## To Date: Resource and networking

- Launched Translation Manchester website (Feb 19)
  - Single point of reference for Translational research
  - https://www.translation.manchester.ac.uk
  - Building and adding resources (pipelines, pathways, webinars)

- Developed a Translation Manchester Network
  - Facilities and resources for translational research in Manchester
  - 30 representative facilities/ resources + 15 to be added <a href="http://documents.manchester.ac.uk/display.aspx?DocID=41839">http://documents.manchester.ac.uk/display.aspx?DocID=41839</a>












## To Date: Translation opportunities in Manchester









## To Date: Gaps and bottlenecks

- Identifying gaps in expertise and opportunities for partnering with industry
  - Database of Manchester cohorts (samples and data)
  - NIHR HIC metadata catalogue

- Facilities and resources to support Translational Research

  Discovery research to gain knowledge
  D1-D4

  Patient centred research
  T1-T3

  In patient, practice, practice
- Identifying bottlenecks and developing roadmaps and webinars to overcome them
  - NIHR BRC Rapid Translation Incubator Workshop: Setting up Experimental Medicine Studies










### To Date: Institutional Hurdles









### Contact

- Laura.Ajram@healthinnovationmanchetser.com
- Andrea.short@Manchester.ac.uk

• <a href="https://www.translation.manchester.ac.uk">https://www.translation.manchester.ac.uk</a>